Join Sensei Biotherapeutics for an investor webcast featuring company leadership and Shiraj Sen, MD, PhD, Medical Oncologist and Director of Clinical Research at NEXT Oncology-Dallas, who will discuss initial results from the dose expansion portion of its Phase 1/2 trial evaluating solnerstotug (formerly SNS-101), a conditionally active monoclonal antibody targeting VISTA (V-domain Ig suppressor of T cell activation) in PD-(L)1 resistant tumors. Dr. Sen is an investigator in the Phase 1/2 study.

A live question and answer session will follow the formal presentations.